Abstract | Lipid-mediated signalling regulates a plethora of physiological processes, including crucial aspects of brain function. In addition, dysregulation of lipid pathways has been implicated in a growing number of neurodegenerative disorders, such as Alzheimer's disease (AD). Although much attention has been given to the link between cholesterol and AD pathogenesis, growing evidence suggests that other lipids, such as phosphoinositides and phosphatidic acid, have an important role. Regulators of lipid metabolism (for example, statins) are a highly successful class of marketed drugs, and exploration of lipid dysregulation in AD and identification of novel therapeutic agents acting through relevant lipid pathways offers new and effective options for the treatment of this devastating disorder. exert their effects primarily by perturbing cellular membranes through direct and indirect mechanisms. Third, lipids themselves modulate the pathogenic potential of amyloid-β and perhaps tau as well, by affecting their propensity to aggregate. This Review addresses the role of lipid dyshomeostasis in either mediating or modulating key pathological processes associated with AD. Specifically, this Review elaborates on the roles of cellular lipids in the production and aggregation of amyloid-β in mediating AD-associated synaptic dysfunction and in tau pathology.
, which in the majority of cases occurs late in life and without a known cause (sporadic Alzheimer's disease, SAD). Patients with AD display loss of synapses and neurons, as well as extracellular senile plaques and intracellular neurofibrillary tangles (NFTs). Senile plaques consist largely of aggregated amyloid-β peptide, which is liberated from the holoprotein, amyloid precursor protein (APP; also known as amyloid-β A4 protein), by sequential cleavages mediated by the β-secretase β-site APP cleavage enzyme 1 (BACE1) and the γ-secretase complex 1, 2 (BOX 1). Rare but highly penetrant mutations in the genes encoding APP and presenilin 1 and presenilin 2, the catalytic components of the γ-secretase, result in early-onset familial AD (FAD). Intraneuronal accumulation of insoluble aggregates of tau in the form of NFTs is also a pathological hallmark of AD 3 . Although under normal conditions tau binds and stabilizes micro tubules in axons, a plethora of studies indicate that under pathological conditions, tau becomes hyperphosphorylated. This phenomenon causes the detachment of tau from microtubules and promotes the formation of insoluble tau aggregates, thus leading to the occurrence of paired helical filaments and NFTs present in brains with AD 3 . Although AD-associated cognitive dysfunction is shown to correlate strongly with the accumulation of amyloid-β and the severity of tau pathology, the precise relationship between these two pathological AD hallmarks remains poorly understood, particularly in SAD 4 .
Alois Alzheimer originally described a third pathological hallmark of AD, which was largely ignored by scientists in the field at its infancy, perhaps owing to the lack of appropriate analytical tools. Indeed, brains with AD display a higher occurrence of 'adipose inclusions' or 'lipoid granules' , suggesting aberrant lipid metabolism 5 . Subsequently, biochemical alterations of lipid composition have been reported in post-mortem brain tissue derived from individuals with AD. However, an intimate link between lipid metabolism and AD was only established when the ε4 allele of the apolipo protein E (APOE) gene was identified as the strongest genetic risk factor for AD 6, 7 . APOE encodes a ~34-kDa protein that serves as a crucial regulator of cholesterol metabolism in the brain and of triglyceride metabolism throughout the body. It mediates the uptake of lipoprotein particles in the brain via the low-density lipoprotein (LDL) receptor related protein (LRP) and the very low-density family lipoprotein receptor (recently reviewed by REFS 8, 9) . The role of the ε4 allele of APOE in amyloid pathology is supported by evidence that it binds amyloid-β and modulates the aggregation and clearance of amyloid-β. Additionally, several epidemiological studies now support a role for cholesterol in the pathogenesis of AD 8, 9 .
It is now well established that most, if not all, classes of lipids are implicated in AD pathogenesis, which can be reconciled with the following facts. First, lipids regulate the trafficking and/or proteolytic activity of membrane-bound proteins that play a fundamental part in this disorder, including APP, BACE1 and the presenilins. Second, cytotoxic entities responsible for key phenotypic manifestations of AD, such as amyloid-β, exert their effects primarily by perturbing cellular membranes through direct and indirect mechanisms. Third, lipids themselves modulate the pathogenic potential of amyloid-β and perhaps tau as well, by affecting their propensity to aggregate. This Review addresses the role of lipid dyshomeostasis in either mediating or modulating key pathological processes associated with AD. Specifically, this Review elaborates on the roles of cellular lipids in the production and aggregation of amyloid-β in mediating AD-associated synaptic dysfunction and in tau pathology.
Regulation of amyloidogenesis by lipids APP, BACE1 and the components of the γ-secretase complex are transmembrane proteins. Consequently, lipid bilayer composition and organization have a substantial impact on trafficking properties, as well as the proteolytic activities, of β-and γ-secretases 10 . Here, the role of cholesterol and other membrane lipid families in APP metabolism and secretase activity will be reviewed.
Role of cholesterol metabolism and transport in amyloidogenesis. In the brain, cholesterol is present mainly in its unesterified form in myelin sheaths and the cellular membranes of glial cells and neurons 11 . Within the cells, the biggest reservoirs of cholesterol are found at the plasma membrane as well as in the endocytic recycling compartment 12 .
Since the blood-brain barrier prevents any efficient exchange between brain and plasma lipoproteins, the majority of brain cholesterol is derived from de novo biosynthesis, rather than from plasma LDL 11, 13 (FIG. 1). Excess free cholesterol in the cell is converted into cholesteryl esters by the enzyme sterol O-acyltransferase 1 (ACAT1; also known as acyl CoA:cholesterol acyltransferase 1) (FIG. 1; Supplementary information S1 (box)), followed by accumulation in intracellular lipid droplets or efflux through the plasma membrane into the extracellular environment 14 . Increasing levels of cholesteryl esters enhances amyloid-β release in cultured cells, whereas pharmacological inhibition of ACAT1 (for example, using CP-113,818) leads to the reduction of both amyloid-β and cholesteryl ester [15] [16] [17] (FIG. 1) .
Genetic ablation of ACAT1 reduces both amyloid-β pathology and cognitive impairments in a mouse model of AD 18 . However, complicating the interpretation, ACAT1 ablation also increases levels of oxysterol, 24(S)-hydroxycholesterol (Supplementary information S1 (box)), suggesting a potential role of this cholesterol metabolite in decreasing amyloidogenesis 16, 18 . One putative mechanism consistent with these results is that the excess free brain cholesterol resulting from ACAT1 ablation can be converted into 24(S)-hydroxycholesterol and subsequently cross the blood-brain barrier to reach the periphery, thus leading to reduced brain cholesterol levels. Together, these data suggest that the balance between free cholesterol and cholesterol esters is a key parameter controlling amyloidogenesis, although the molecular basis underlying this relationship is unclear 16 . Several lines of evidence indicate that cholesterol efflux also controls amyloid-β generation (FIG. 1) . ATPbinding cassette transporter A1 (ABCA1) serves as an important regulator of the levels and lipidation status of APOE by stimulating efflux of excess intracellular cholesterol to extracellular lipid acceptors, including unlipidated APOE 19, 20 . Increased levels of ABCA1 were found to lower amyloid-β levels in cultured cells 21 . Conversely, in vivo studies showed that deletion of ABCA1 gene in mouse models of AD dramatically decreases the levels of APOE both in the brain and in the periphery, which correlates with greater amyloid-β deposits [22] [23] [24] . As residual APOE in ABCA1-deficient mice is poorly lipidated, it was speculated that the low levels of APOE lipidation, rather than the low levels of APOE per se, promote
Box 1 | The amyloid cascade hypothesis
The amyloid cascade hypothesis supports the idea that amyloid-β (Aβ) peptide plays a central and even causative part in Alzheimer's disease (AD) 1, 2 . Cleavage of amyloid precursor protein (APP; also known as amyloid-β A4 protein) by β-site APP cleavage enzyme 1 (BACE1) liberates its soluble ectodomain (sAPPβ) into the extracellular space. The resulting cell-associated COOH-terminal fragments, which can be either 99 or 89 amino acids in length (termed C99 or C89), are subjected to intramembrane proteolysis mediated by γ-secretase, which generates a spectrum of Aβ peptides of varying length at the COOH terminus as well as the APP intracellular COOH-terminal domain (AICD) 1, 2 . The predominant species of Aβ is 40 amino acids long (Aβ40), but the less abundant 42-amino-acid variant (Aβ42) is more amyloidogenic and is the initial Aβ species that deposits into amyloid plaques in all forms of AD 1, 2 . Cleavage of APP within the Aβ sequence by α-secretase followed by γ-secretase cleavage, the non-amyloidogenic pathway, results in the production of a shorter, possibly innocuous APP fragment (p3), along with the secreted ectodomain (sAPPα) and AICD 1, 2 . Although brains with AD typically harbour senile plaques that consist of insoluble aggregates of Aβ, different assemblies of Aβ, including fibrils as well as soluble dimers, trimers and dodecamers, may differentially contribute to AD pathogenesis at various stages of this disorder 1, 2 . Importantly, elevation of soluble Aβ oligomers strongly correlates with cognitive decline, consistent with the synaptotoxic properties exhibited by these peptides in various systems 1, 2 . In summary, the modern amyloid cascade hypothesis takes into consideration the various assembly states of Aβ. The figure shows the amyloidogenic proteolytic processing of APP leading to the production of Aβ and the role of this peptide in various assembly forms in the pathophysiological progression of AD. C, carboxy-terminal; N, amino-terminal; PHF, paired helical filaments. . Alternatively, the latter phenomenon may be accounted for by accumulation of intracellular cholesterol as a result of decreased efflux 19 .
Role of cellular cholesterol and lipid rafts in amyloidogenesis. Cholesterol can directly modulate secretase activities leading to altered amyloid-β generation (FIG. 2) . Reducing membrane cholesterol levels through cholesterol-extracting compounds, such as β-methyl cyclodextrin (βMCD), decreases activity of both BACE1 and γ-secretase, leading to an additive reduction in amyloid-β generation 10, 25, 26 . Additionally, cell-free assays indicate that high cholesterol content directly influences the activity of recombinant BACE1 in reconstituted unilamellar vesicles 27 (FIG. 2a,c) .
Treatment of cholesterol-enriched vesicles containing BACE1 with βMCD reduces the amount of membraneassociated BACE1, suggesting that cholesterol-enriched microenvironments could directly influence the activity of BACE1. Cholesterol levels also directly regulate γ-secretase-mediated production of amyloid-β 25, 28, 29 ( FIG. 2c) . Inclusion of cholesterol or sphingolipids in phosphatidylcholine-containing vesicles leads to increased γ-secretase activity 30, 31 . Together, these in vitro data are consistent with a role of cholesterol-and sphingolipidenriched membrane microdomains called 'lipid rafts' (BOX 2) in the amyloidogenic processing of APP.
Despite the fact that pools of APP, BACE1 and presenilin are present in both raft and non-raft regions of the membranes, APP processing occurring within lipid rafts appears to be largely amyloidogenic, whereas outside lipid rafts, APP is processed predominantly by the non-amyloidogenic, α-secretase pathway 10, 26 (FIG. 2) . A substantial pool of BACE1 is localized to lipid rafts 32, 33 mainly through palmitoylation of its transmembrane and cytoplasmic domains 34, 35 . Cholesterol depletion decreases the association of BACE1 with lipid rafts, which correlates with decreased amyloidogenic processing of APP 32, 33, 36 (FIG. 2a) . By contrast, acute cell exposure to cholesterol promotes the co-clustering of APP and BACE1 in lipid raft domains, as well as their rapid endocytosis 37 . Introduction of a glycosylphosphatidylinositol (GPI) anchor, a targeting motif for lipid raft localization, into the BACE1 sequence strongly promotes amyloidogenic processing of APP 10, 26 , further supporting the key role of the BACE1-raft association in amyloid-β generation. Collectively, these studies suggest that cholesterolsensitive amyloid-β production is determined, at least in part, by the levels of BACE1 present in lipid rafts. Cholesterol in the brain is mainly derived from de novo synthesis from the endoplasmic reticulum (ER). Small amounts of cholesterol can also be delivered to the brain from the periphery through high density liproproteins (HDLs), which can cross the blood-brain barrier (BBB), whereas larger lipoproteins such as low-density lipoproteins and very low density lipoproteins (LDL/VLDL) are unable to do so (shown by the red cross). 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase mediates the rate-limiting step in de novo cholesterol biosynthesis. Excess free cholesterol is converted into cholesterol ester by sterol O-acyltransferase 2 (ACAT; also known as acyl CoA:cholesterol acyltransferase 1). Inhibition of HMG-CoA reductase by statins leads to decreased levels of Aβ in animal models and ACAT inhibition has been also shown to reduce Aβ levels by a mechanism that remains as yet poorly defined. APOE-containing HDL-like particles inhibit the aggregation of Aβ, whereas free APOE has been shown to promote Aβ aggregation. LDL receptor-related protein (LRP) serves as a neuronal receptor for astrocyte-produced APOE-containing lipid particles, thus mediating their internalization into neurons where they are broken down. ABCA1 (ATP-binding cassette sub-family A member 1), a regulator of cholesterol efflux, has been also shown to modulate Aβ levels in neurons. For simplicity, Aβ is drawn as free-floating in the cytoplasm, although it is produced in the lumen of neuronal organelles of the late secretory and endolysosomal systems, from where it can be secreted. However, there may be cell type-specific differences dictating the extent of this relationship. Enhancing the association of APP with lipid rafts also favours amyloidogenic processing 26, 33, 38, 39 . Finally, core components of the γ-secretase complex, including presenilins, are also associated with lipid rafts 26, 29, 40 (FIG. 2) . Accordingly, inhibition of γ-secretase activity leads to the accumulation of APP COOH-terminal products in lipid rafts 26 ( FIG. 2a,c) . By contrast, other γ-secretase substrates, such as Notch 1 and Jagged 2, are largely processed in non-raft compartments 41 . Collectively, these studies suggest that modulating the biophysical properties of rafts to decrease association of APP, BACE1 or presenilins with these lipid microdomains, may offer a therapeutic opportunity to reduce amyloidogenic processing of APP, thus delaying the progression of AD.
Role of sphingolipids in amyloid-β production. In addition to cholesterol, sphingolipids, including ceramide, sphingomyelin and glycosphingolipids (GSLs) (Supplementary information S2 (box)), are major components of lipid rafts, playing a number of crucial parts in cell functions associated with normal as well as diseased states 42, 43 . Ceramide is a central component in sphingolipid metabolism and serves as the backbone to generate sphingomyelin or more complex glycosphingolipids through the addition of phosphocholine or sugars at the hydroxyl group, respectively. Sphingomyelin and GSLs are abundant in the brain, and gangliosides, which are GSLs containing sialic acids, are the major components of neuronal membranes (see below). Early reports show that ceramide levels are elevated at the earliest clinically recognizable stage of AD, perhaps mediating oxidative stress-induced neuronal death 44 . However, ceramide also regulates BACE1-mediated processing of APP independently of its role in oxidative cell death. The mechanism seems to be related to the enhancement of BACE1 stability in cells, perhaps through the formation of ceramide-enriched platforms 45, 46 (FIG. 2c) .
Sphingolipids are also directly involved in APP metabolism. Inhibition of sphingomyelinase, the enzyme that mediates the conversion of sphingomyelin to ceramide, and the resulting sphingomyelin accumulation, reduces amyloid-β secretion owing to inhibition of γ-secretase activity 47 (FIG. 2c) . Enhanced sphingomyelinase activity is also detected in cells harbouring FAD mutations in PS1, further indicating an important role for sphingolipids in AD 47 . However, suppression of the entire sphingolipid biosynthetic pathway by inhibition of serine palmitoyl transferase leads to increased production of amyloid-β 42 (Aβ42; the 42-amino-acid form of amyloid-β), whereas Aβ40 levels remain unchanged. Subsequent addition of sphingosine restores the normal ratio of Aβ42 to Aβ40, indicating that sphingolipids may act as γ-secretase modulators 48 . Finally, the V3 loopdomain of the amyloid-β peptide has been described as a sphingolipid-binding sequence 49 and confers affinity for this peptide to raft-like sphingolipid-and cholesterolrich regions of cellular membranes, with potentially important implications for the aggregation, internalization and intracellular sorting of amyloid-β, all of which can affect its pathogenic potential 50 . Collectively, these studies show that sphingolipids modulate activity of γ-secretase and BACE1 as well as the microdomain localization of amyloid-β, although further work is needed to elucidate the mechanistic details and to validate these lipid-dependent models in vivo.
Isoprenoids and small GTPases. The 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) pathway, also called the mevalonate pathway, not only leads to the synthesis of cholesterol but also provides eukaryotic cells with essential lipids, such as isoprenoids Several lipids (shown in blue boxes) and lipid metabolizing proteins (shown in yellow boxes) influence APP processing through a variety of mechanisms. a | The amyloid precursor protein (APP; also known as amyloid-β A4 protein) undergoes amyloidogenic processing mediated either by β-and γ-secretases to yield amyloid-β (Aβ) peptide (shown by purple rectangles). Amyloidogenic processing of APP largely occurs in lipid rafts. Cholesterol and low-density lipoprotein (LDL) receptor-related protein (LRP), an apolipoprotein E (APOE) receptor, promote the localization of β-site APP cleavage enzyme 1 (BACE1) to lipid rafts. GGPP (geranylgeranyl pyrophosphate, a short chain isoprenoid) has been shown to promote the association of the γ-secretase complex with lipid rafts. b | APP is also subjected in neurons to a non-amyloidogenic pathway mediated by α-secretase. Localization of APP to non-lipid raft compartments favours processing by α-secretase. Isoprenoids, diaglycerol and phospholipase C (PLC) have been shown to promote the non-amyloidogenic pathway. c | The relative abundance or absence of the lipids listed (shown in the blue boxes) directly influences the activity of BACE1 or γ-secretase. Increased levels of cholesterol or ceramide enhance the activity of BACE1. Cholesterol and sphingolipids are positive modulators of γ-secretase activity, whereas sphingomyelinase (SMase) and phospholipase D1 (PLD1) have been identified as negative modulators of γ-secretase activity. PLC-mediated hydrolysis of PtdIns(4,5)P 2 promotes amyloidogenesis by stimulating γ-secretase activity and PtdIns(4,5)P 2 has been shown to directly inhibit γ-secretase activity.
(recently reviewed in REF. 51 ) (Supplementary information S1 (box)). Thus, statins, which block HMGCoA reductase, may also exert their effects through cholesterol-independent mechanisms 52 . Long-chain isoprenoids play a part in membrane organization and protein glycosylation (for example, dolichol) as well as mitochondrion respiration (for example, ubiquinone or coenzyme Q). By contrast, short-chain isoprenoids farnesylpyrophosphate (FPP) and its metabolite geranylgeranylpyrophosphate (GGPP) are utilized for the isoprenylation of a wide variety of proteins, including nuclear lamins and small GTPases of the Ras, Rho and Rab families. Small GTPases act as molecular switches in a myriad of signalling and trafficking pathways and their isoprenylation, referred to as farnesylation and geranylgeranylation, allows for recruitment to the cytosolically-exposed leaflets of cellular membranes, where they exert their signalling actions. Recent evidence suggests that a perturbation of the metabolism of FPP and GGPP -and hence, GTPase signalling -occurs in AD 51, 53 . This phenomenon is likely to be relevant for AD pathogenesis because GTPase signalling can control multiple aspects of amyloidogenesis, including the trafficking of APP, BACE1 and γ-secretase.
Although long-chain isoprenoids were reported to be altered in brains with AD two decades ago 54 , more recent studies have established that GGPP and, to a lesser extent, FPP are significantly elevated in the frontal cortex of patients with AD, consistent with increased levels of their respective synthases 55 . Importantly, pharmacological studies in various model systems, including in mice, have implicated short-chain isoprenoids as primary regulators of APP metabolism. Indeed, a search for the mechanism governing the Aβ42-lowering action of non-steroidal anti-inflammatory drugs (NSAIDs) has identified the activation of RHO family small GTPases and their effectors -members of the RHO-associated kinase (ROCK) family as potential mediators of this effect 56 , although alternative mechanisms have also been proposed 57 . Although isoprenylation has been proposed to modulate the specificity or activity of γ-secretase in Aβ42 generation 40, 58 , statins were shown to promote ectodomain shedding of APP through the α-secretase pathway in a cholesterol-independent manner by inhibiting isoprenoid-mediated signalling involving proteins from the RHO and ROCK families, in favour of the nonamyloidogenic processing of APP 59 (FIG. 2b) . However, lowering isoprenoid levels while maintaining normal cholesterol levels alters the traffic of APP, leading to accumulation of β-COOH-terminal fragments (βCTFs) and intracellular amyloid-β, suggesting that processing through the β-secretase pathway is enhanced 60 (FIG. 2c) .
Collectively, these studies indicate that isoprenylation differentially modulates all three secretase activities and underscores the pleiotropic effects of statins on APP metabolism by identifying cholesterol-and isoprenoid-specific processes.
Role of phospholipids in amyloid-β production. Early studies on brain tissue from patients with AD reported alterations in the composition and metabolism of several phospholipids, including phosphoinositides (that is, phosphorylated derivatives of phosphatidylinositol), as well as changes in the levels of several phospholipid-metabolizing enzymes, such as phospholipase A2 (PLA2), phospholipase C (PLC) and phospholipase D (PLD), and phosphoinositide kinases and phosphatases 61, 62 . Additionally, wortmannin, a classical inhibitor of the phosphatidylinositol 3-kinase (PI3K) pathway was shown to reduce the levels of amyloid-β both in vitro and in vivo, thus further highlighting a potential role of phosphoinositides in AD pathogenesis 63, 64 . Phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P 2 ), the most abundant and best characterized species of phosphoinositides, is predominantly implicated in functions related to the plasma membrane 65 . Insight into its role in amyloidogenesis was provided by the finding that reconstituted γ-secretase complex activity in liposomes is exquisitely sensitive to the presence of PtdIns(4,5)P 2 . This inhibitory effect on APP cleavage was proposed to reflect competitive interference between PtdIns(4,5)P 2 and the substrate for their interaction with the γ-secretase complex 30, 31 . Further studies have shown that cellular PtdIns(4,5)P 2 levels inversely correlate with secreted Aβ42 levels in cultured fibroblasts 66 . The same study showed that enhanced turnover of PtdIns(4,5)P 2
Box 2 | Lipid rafts
Lipid rafts are heterogenous, cholesterol-and sphingolipid-rich membrane microdomains that mediate compartmentalized cellular processes by clustering receptors and signalling molecules [140] [141] [142] [143] . In addition to cholesterol and sphingolipids, these dynamic lipid-protein assemblies are enriched in saturated glycerophospholipids and protein molecules with a high inherent affinity for ordered lipid domains. Raft lipids are believed to be held together by relatively weak covalent bonds, establishing a dynamic equilibrium of raft and non-raft regions within the plasma membrane 140 . The sphingolipids interact laterally through van der Waals interactions and extensive hydrogen bonding between the sphingosine backbones and between the sugar head groups 144 . Moreover, the majority of sphingolipids have saturated, and therefore unkinked, acyl chains that allow tighter packing of laterally associated lipids and a higher gel-liquid phase transition temperature 145 . These interactions lead to segregation of sphingolipid-rich domains from their glycerophospholipid-rich surroundings. The degree of lateral association is further increased by the presence of cholesterol. The 3β-hydroxyl group of cholesterol hydrogen bonds with the ceramide group of sphingolipids, whereas its planar sterol ring interacts with the saturated acyl chain 144, 146 . Growing evidence indicates that the amyloidogenic processing of amyloid precursor protein (APP; also known as amyloid-β A4 protein) occurs in lipid rafts, largely because functionally active pools of BACE1 and γ-secretase are present in these microdomains, alongside a pool of APP. A popular idea is that decreasing the association of these proteins with lipid rafts may be beneficial in AD, although the extent to which this approach would interfere with their physiological functions must be considered. β through the PLC pathway is a consequence of FADassociated mutations in the presenilin genes. Reduction of PtdIns(4,5)P 2 turnover with a PLC inhibitor both decreases Aβ42 secretion and prevents Ca 2+ entry, deficits commonly associated with these mutations 66, 67 (FIG. 2c) .
Although this raises possible opportunities to target the PLC pathway therapeutically, PLC-mediated PtdIns(4,5) P 2 hydrolysis produces diacylglycerol, which in turn stimulates α-secretase through protein kinase C-dependent and -independent mechanisms 68 (FIG. 2b) . Blocking PLC would therefore indirectly reduce the activity of the non-amyloidogenic α-secretase and may thus indirectly enhance amyloidogenesis. Overall, it remains to be seen whether inhibition of PLC would be beneficial or not in AD.
The PLD pathway has also been shown to play a part in amyloidogenesis 62 . Most studies on the link between PLD and amyloidogenesis have so far focused on PLD1, which, like related family member PLD2, hydrolyses phosphatidylcholine to generate phosphatidic acid and free choline 62, 69 (FIG. 3) . Phosphatidic acid is a bioactive lipid that mediates signalling processes as well as membrane budding and fusion along the secretory, endolysosomal and autophagy pathways 69, 70 . PLD1 overexpression was shown to promote the cell surface delivery of APP and neurite outgrowth in primary hippocampal neurons expressing FAD mutant versions of PS1 -two processes that are defective in mutant neurons. Additionally, PLD1 negatively regulates the processing of APP by PS1, probably through modulation of PS1 activity 62, 71, 72 (FIG. 2b) . PLD1 also promotes the cell surface delivery of PS1 and physically interacts with this protein 71, 73 . Future studies are needed to establish whether PLD1 modulates AD pathogenesis through the aforementioned mechanisms in vivo and whether it involves crosstalk with the metabolism of PtdIns(4,5)P 2 , as its synthesis is stimulated by phosphatidic acid 69 . In summary, studies on phospholipids, such as phosphoinositides and phosphatidic acid, have implicated these lipids in several processes controlling amyloid-β generation, including the trafficking of APP and presenilin. This area therefore has the potential to be explored for novel therapeutic interventions. Amyloid-β oligomers interact with a number of cell surface molecules, such as the major prion protein (PrP), gangliosides (for example, GM1) and Ca
2+
-permeable neurotransmitter receptor channels (for example, the NMDA and α7 nicotinic acetylcholine receptors (α7nAchRs)), to influence neuronal activity and synaptic function in neurons. Some of these receptor channels, such as the NMDA receptor, are crucial for synaptic plasticity and are involved in learning and memory. A variety of amyloid-β oligomer species have been shown to potently alter synaptic function, in part by enhancing the activity of phospholipase C (PLC), cytosolic phospholipase A2 (cPLA2) and phospholipase D2 (PLD2). PLC hydrolyses phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P 2 ) to diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (-Ins(1,4,5)P 3 ). cPLA2 hydrolyses phosphatidylcholine (PC) to arachidonate and lysophosphatidylcholine (LPC). PLD2 hydrolyses PC to phosphatidic acid (PA) and choline. The crosstalk and functional hierarchy among these phospholipases remain to be determined, although a common denominator for their activation appears to be elevation of intracellular Ca
. Decreased dephosphorylation of PtdIns(4,5)P 2 to phosphatidylinositol-4-phosphate (PtdIns4P) resulting from the heterozygous deletion of phosphoinositide phosphatase synaptojanin 1 (SYNJ1) confers protection against the synaptotoxic action of amyloid-β oligomers, indicating that phospholipid metabolism can directly influence the susceptibility of neurons to amyloid-β. DAGK, diacylglycerol kinase; NMDAR, NMDA receptor; PAP, phosphatidic acid phosphatase; PIP5K1, phosphatidylinositol-4-phosphate 5-kinase type-1 family member; PtdIns4P, phosphatidylinositol-4-phosphate.
Role of lipids in amyloid-β aggregation
Amyloid-β is released in the lumen of organelles from the late secretory and endosomal systems, as well as in the extracellular environment. Amyloid-β is believed to exert its toxic effects by interacting with cellular membranes and their associated proteins, which in turn modulate the folding of this peptide into higher-order structures of varying cytotoxic potential 74, 75 . These amyloid-β species have the ability to perturb the integrity and signalling properties of membranes with which they interact. Thus, membrane-bound assembly-(or aggregate-) promoting factors, such as gangliosides, have received considerable attention.
Gangliosides are abundant membrane glycosphingolipids that are primary modulators of amyloid-β aggregation 74, 75 (Supplementary information S2 (box)). They are concentrated in the luminal leaflet of various cellular organelles and the outer leaflet of the plasma membrane, where they are found in raftlike lipid microdomains that also contain cholesterol. The processing of the ganglioside precursor ceramide by different enzymes results in either a-series, b-series or o-series gangliosides. The main gangliosides in the brain are GM1 and GD1a (a-series) and GD1b and GT1b (b-series) 43 . A link between gangliosides and AD was first suggested by studies showing aberrant expression levels and significant regional differences in the distribution of specific gangliosides in brains with AD 76, 77 . Importantly, gangliosides, such as GM1, bind amyloid-β and alter the conformation from random coils to more ordered structures with increased β-sheet content, which correlates with toxicity. Thus, cell surface GM1 acts as a 'seed' for amyloid-β aggregation in neurons as well as in nerve terminal preparations. The seeding property of GM1 increases with the ageing process and is facilitated by cholesterol-rich environments, indicating that the process might occur in membrane rafts 75, 78 . Interestingly, the presence of GM1-bound amyloid-β (GAβ) is associated with early pathological changes in AD 79 . FAD mutations within the amyloid-β sequence alter the ganglioside-binding specificity, perhaps accounting in part for differences in the phenotypic manifestations associated with individuals in families affected by FAD.
Genetic evidence now strongly supports the hypothesis that gangliosides may be key disease-modifiers and modulators of amyloid-β deposition. Ablation of Beta -1,4 N-acetylgalactosaminyltransferase 1 (also known as GM2/GD2 synthase) in a transgenic mouse model of AD leads to an accumulation of GM3 and a loss of GM1. This results in the accumulation of amyloid-β in brain parenchyma and, more interestingly, in vascular smooth muscle tissue. This vascular deposition is reminiscent of the amyloid angiopathy occurring in patients carrying the Dutch APP mutation, which lies within the amyloid-β sequence and enhances the affinity of amyloid-β for GM3 (REF. 78 ). Perhaps more relevant for therapeutics, genetic ablation of GD3 synthase (GD3S) improves cognitive function and decreases the amyloid-β plaque burden in a bigenic mouse expressing FAD mutant versions of the APP and PSEN1 genes 80 .
Although amyloid-β fails to bind and exert neurotoxicity on GD3S-null neurons and astrocytes, the precise nature of the protective mechanism conferred by GD3S ablation is unclear. In GD3S-null cells, the decrease in b-and c-series gangliosides is concomitant with an increase in a-series, such as GM1 and GM3 (REF. 80) (Supplementary  information S1) . Potential benefits that are derived from ganglioside-based therapies are highlighted by studies in a transgenic model of AD, in which injections of GM1 were shown to decrease amyloid-β burden, possibly by promoting degradation of amyloid-β in the periphery 81 . Finally, gangliosides associated with amyloid-β in neuritic plaques may mediate evasion from immune surveillance by interacting with a negative immune receptor expressed in microglia -siglec 11. Thus, gangliosides may indirectly facilitate the formation and maintenance of amyloid plaques by decreasing clearance through microglial degradation 82 .
Lipids and amyloid-β-mediated synaptotoxicity Amyloid-β exerts its neurotoxicity primarily by interacting with cellular membranes, leading to impairment of integrity and signalling properties. Synapses are particularly affected, not only because they are major sites of amyloid-β release but also because amyloid-β release itself is enhanced by synaptic activity 83, 84 . Furthermore, oligomeric assemblies of amyloid-β appear to have high affinity for synaptic membranes, particularly dendritic spines 85 . As synaptic dysfunction is likely to be the primary cause of cognitive impairment in the early stage of AD 1, 86 , it is of paramount importance to fully understand the synaptotoxic signalling pathway dictated by amyloid-β and, in particular, the role of lipid changes in mediating this pathway. Central to the action of amyloid-β on lipid metabolism seems to be the ability of this peptide to perturb calcium homeostasis 87 and the subsequent dysregulation of calcium-sensitive phospholipid-metabolizing enzymes (FIG. 3) .
Inositol lipids, phospholipase C and synaptojanins. Early studies of brains with AD showed a reduction in the levels of PtdIns 61 and an increase in PLC activity as a result of amyloid-β application on membrane fractions 88 or owing to expression of FAD mutants of presenilin 66, 89 . Insights into the underlying mechanism have been provided by a recent study indicating that amyloid-β itself disrupts the metabolism of PtdIns(4,5)P 2 and that this phenomenon is required for its synaptotoxic action 90 (FIG. 3) . Indeed, PtdIns(4,5)P 2 levels decreased upon acute and chronic exposures to oligomeric Aβ42 at nanomolar concentrations. This effect required extracellular Ca 2+ as well as PLC activity, and partially depended on NMDA receptor function (FIG. 3) . Blocking PtdIns(4,5)P 2 breakdown by genetically reducing the level of a phosphoinositide phosphatase, synaptojanin 1, prevented Aβ42 oligomers from suppressing long-term potentiation (LTP) in hippocampal slices 90 (FIG. 3) . As synaptojanin 1 regulates clathrin-mediated synaptic vesicle recycling and the internalization of AMPA receptors 65, 91, 92 , haploinsufficiency of the synaptojanin 1 (SYNJ1) gene may counteract the ability of Aβ42 oligomers to perturb the synaptic vesicle cycle presynaptically or promote the internalization of AMPA receptors (and perhaps also NMDA receptors) at the postsynapse, both of which are central to amyloid-β-mediated depression of synaptic transmission 93, 94 . By contrast, the overexpression of SYNJ1 owing to triplication of chromosome 21, where SYNJ1 is located, and the resulting deficiency of PtdIns(4,5)P 2 , correlate with learning deficits in transgenic mouse models of trisomy 21 (or Down's syndrome) 95 . Because middle-aged individuals with Down's syndrome develop AD pathology, including senile plaques, these studies suggest the intriguing possibility that trisomy 21-linked SYNJ1 overexpression may confer a sensitized background for the synaptotoxic effects of amyloid-β. The combined actions of SYNJ1 and amyloid-β may inflict a dual 'hit' upon PtdIns(4,5)P 2 in the brains of individuals with Down's syndrome.
Although conversion of PtdIns(4,5)P 2 to PtdIns(3,4,5) P 3 by class I PI3Ks is key to cell survival, recent evidence suggests that it may paradoxically mediate synapseand memory-impairing actions of amyloid-β in a fly model of AD 96 . Indeed, expression of a secretory form of Aβ42 in the fly brain was shown to decrease long-term depression and to induce an age-dependent increase in oligomeric and fibrillar Aβ42, which parallels memory loss and neurodegeneration. Whether these defects in PI3K signalling occur in mammalian neurons and more generally in brains with AD remains to be discovered.
Arachidonic acid and phospholipase A2. Release of arachidonic acid from phospholipids through the PLA2 pathway (FIG. 3; Supplementary information S3) produces a large family of metabolites, including prostaglandins and leukotrienes 97 . PLA2 products and their metabolites have been implicated in several AD-relevant aspects, including inflammation, glutamatergic transmission, synaptic plasticity and oxidative stress. Important clues implicating dysregulation of the PLA2 pathway in AD stemmed from post-mortem studies showing an increase in the immunoreactivity of cytosolic PLA2 (REF. 98 ) and a reduction in the levels of phospholipid-bound arachidonic acid in brains with AD 99 . Other studies have identified cytosolic PLA2 as a key mediator of amyloid-β oligomer-induced neuronal cell death acting in a cascade involving reactive oxygen species (ROS) formation and leading to downstream activation of a sphingomyelinaseceramide pathway triggering apoptosis 100, 101 . Recently, Mucke and colleagues used an unbiased approach to profile essential fatty acid metabolism in various brain regions from a transgenic model of AD ('J20'), which is associated with a significant age-dependent accumulation of amyloid-β 102, 103 . An increase in arachidonic acid as well as in various metabolites of this fatty acid was found selectively in the hippocampus. This led to the identification of a specific isoform of PLA2, group IV A (GIVA), which is Ca 2+ -dependent, highly expressed in the brain and hyperactivated in AD 102, 103 . Importantly, genetic ablation of GIVA PLA2 improved cognition, viability and behaviour, in the context of the J20 APP transgenic model, despite the elevated amyloid-β burden 102 . A partial mechanistic understanding of amyloid-β-mediated neurotoxicity was provided by data showing that GIVA PLA2 activation by amyloid-β and direct applications of the product arachidonic acid both stimulate AMPA-mediated excitotoxicity in acutelytreated primary neuronal cultures by elevating the cell surface levels of AMPA receptor 102, 103 . Thus, GIVA PLA2 is likely to be one of the key Ca 2+ effectors mediating the acute and chronic synaptotoxic actions of amyloid-β.
Phosphatidic acid and phospholipase D. Several early post-mortem studies reported changes in PLD activity in brains with AD 62 , a link that was corroborated by studies in cell culture models showing that APP overexpression and extracellular amyloid-β applications enhance PLD activity 62 . Recently, robust in vitro and in vivo evidence has been provided for a role of the PLD2 isoform in mediating the synaptotoxic actions of amyloid-β 104 . Indeed, it was found that Aβ42 oligomers enhance total PLD activity in primary cortical neurons and that this increase is abolished in mouse neurons lacking PLD2. Evidence indicating that PLD2 is required for the synaptotoxic action of Aβ42 was provided by data showing that genetic ablation of this enzyme confers protection against the suppressive effects of Aβ42 on LTP and memory impairment in a mouse model of AD expressing mutant APP (swAPP) 104 (FIG. 3) . Using mass spectrometry, this study also identified a molecular species of phosphatidic acid that is controlled by PLD2, selectively upregulated in response to swAPP overexpression and has been previously linked to neurodegeneration 104, 105 . Thus, specific pools of phosphatidic acid and PLD2 are likely to play a key part in AD pathogenesis, although the molecular basis for this phenomenon is unknown.
Regulation of cholesterol homeostasis and sphingolipid metabolism by amyloid-β. Amyloid-β is known to regulate the metabolism of cholesterol and sphingolipids, both of which also affect APP processing 47, 106 . Indeed, Aβ40 suppresses the mevalonate pathway by inhibiting HMG-CoA reductase, thus decreasing the levels of cholesterol 106 . Additionally, whereas micromolar concentrations of Aβ42 induce oxidative stress and neurotoxicity by enhancing ceramide production through activation of neutral sphingomyelinase 101 , physiologically relevant concentrations of Aβ42 (that is, ranging from low pM to nM) stimulate neutral sphingomyelinase hydrolysis and ceramide production through the same enzyme without affecting cell viability 47, 106 . A growing number of studies point to the role of low, physiological (picomolar) amyloid-β concentrations in synaptic function -for example, REF. 107 , in which it is suggested that regulation of lipid metabolism by APP and its metabolites may be relevant to neuronal physiology, although the signalling pathways involved are poorly understood.
Linking lipid metabolism to tau pathology In contrast to APP and the secretases (which are membranebound), tau is a cytoplasmic protein that interacts with, and stabilizes, microtubules. Although several types of membranous organelles crucially depend on microtubules for their subcellular localization and intracellular transport, the relationship of tau with lipids is not direct. However, tau (and tau pathology) can be modulated by lipids in several ways. First, the amyloid-β signalling pathway, as highlighted above, perturbs biochemical pathways involving lipid metabolizing enzymes and bioactive lipids, ultimately affecting tau phosphorylation 108 . Second, cholesterol levels are a key parameter controlling amyloid-β-induced tau proteolysis by calpain 109 , and proteolytic cleavage of tau by this protease, but also by caspases, seems to be an early step leading to tau pathology 110, 111 . A pool of hyperphosphorylated tau is also present in lipid rafts, along with APP metabolites (including dimeric amyloid-β), BACE1, the γ-secretase complex and APOE, suggesting that substantial crosstalk may exist between amyloid-β and tau at the raft interface 112 . Furthermore, there is evidence that kinases implicated in tau phosphorylation, such as cyclindependent kinase 5 activator 1 (CDK5) and glycogen synthase kinase 3β (GSK3β), are activated on cellular membranes and thus dysregulation of lipid metabolism may affect the activity of these kinases 113, 114 . CDK5, in turn, phosphorylates the lipid kinase VPS34 (phosphatidylinositol 3-kinase catalytic subunit type 3) 115 , whose product PtdIns3P may regulate the clearance of tau aggregates by stimulating the autophagy pathway 116 . Finally, a growing scientific community is investigating the mechanisms through which tau aggregates may be secreted or exert their prion-like infectious properties across cell membranes, thus propagating the tau pathology 117 . Membrane lipids may therefore modulate these processes.
Although the link between lipid dysregulation and tau pathology is not well understood in AD, the occurrence of neurofibrillary tangles in the brains of individuals with lipid storage disorders, such as Niemann-Pick type C (NPC) disease, suggests a tight relationship between lipid trafficking defects and tau pathology 118 . NPC is an inherited autosomal recessive neurodegenerative disorder that causes childhood or early adulthood death and stems from mutation in either of two functionally related genes, NPC1 and NPC2, which encode late endosome-and lysosome-enriched proteins proposed to be involved in the trafficking of cholesterol 119 . Loss-of-function mutant versions of NPC1 or NPC2 result in higher endosomal levels of unesterified cholesterol and sphingomyelin in peripheral tissues as well as of multiple glycosphingolipids in the central nervous system, possibly reflecting the inability of these lipids to efficiently exit this compartment and traffic to their normal destinations in cells 119 . Although NPC is not associated with increased amyloid-β plaque burden, the lipid trafficking defect in NPC has been linked to enhanced amyloidogenic processing of APP in endosomes. As in AD, the relationship between tau pathology and aberrant APP metabolism is unclear, although the emerging notion of a central role for lipid trafficking defects and endosomal dysfunction in NPC suggests the existence of shared pathogenic mechanisms between this disorder and AD
119
.
Lipid-focused therapeutic approaches Despite a myriad of studies connecting lipid metabolism to AD pathogenesis, relatively few therapeutic approaches have exploited this connection thus far, with the exception of drugs affecting cholesterol metabolism, such as statins and ACAT1 inhibitors. Indeed, current drug development strategies mainly rely on the repositioning of existing therapeutic agents that have originally been developed for other disease indications, such as atherosclerosis. This section will summarise progress made with such therapeutic agents and elaborate on promising new leads that stem from research on phospholipids as well as lipid-based nutritional agents.
Statins and ACAT inhibitors. As mentioned above, statins inhibit the enzyme HMG-CoA reductase which catalyses the rate-limiting step in cholesterol biosynthesis (Supplementary information S1). Retrospective case control studies suggest that statins reduce the risk of developing AD 120, 121 , but clinical trials and prospective cohort studies have produced inconsistent, mixed results 122, 123 . One of the more encouraging studies showed that statins prevent brain trauma-induced amyloid-β elevation in mice, raising the possibility that an activity-or injury-dependent, statin-sensitive pool of amyloid-β may be present in the brain 124 . This is relevant because brain trauma may be a major risk factor for AD. Overall, despite early promising indications that statins might slow AD progression through inhibitory effects on amyloidogenesis, anti-inflammatory actions or modification of cardiovascular risk factors 106, 125 , results from clinical studies have been rather disappointing.
A more recent therapeutic approach involves small molecule inhibitors of ACAT1, an enzyme that mediates the esterification of cholesterol, as discussed above (Supplementary information S1 (box)). CP-113,818 and CI-1011 have demonstrated efficacy in preclinical models of AD 16, 17 . However, important challenges to be overcome inthe development of ACAT inhibitors for the treatment of AD include addressing safety concerns and enabling them to cross the blood-brain barrier. Additionally, more research is needed to better understand the molecular mechanisms underlying the amelioration of AD phenotypes by these compounds.
Emerging lipid-centric therapeutic approaches. Genetic, pharmacological and cell biological studies continue to explore the possibility of targeting effectors and pathways of lipid metabolism relevant to AD. Although many molecular targets, including cytosolic PLA2, SYNJ1, PLD2 and neutral sphingomyelinase, are being validated at the genetic level, further studies are needed to assess the 'drugability'(suitability as a therapeutic target) of these targets and identify chemical probes that are suitable for further therapeutic development. Positive modulation of the postsynaptic APOE receptor 2 by reelin also represents a promising avenue, bacause reelin inhibits the synaptotoxic action of amyloid-β by promoting glutamatergic transmission in depressed synapses 126 .
Whereas major research efforts are in progress to identify cellular effectors and enzymes of lipid metabolism, lipids themselves have been considered for therapeutic use as well as preventive agents for AD. Epidemiological studies suggest that reduced intake of omega-3 fatty acids elevates the risk of AD 127 . Docosahexaenoic acid (DHA), the most popular omega-3 fatty acid used as a nutritional supplement, has been shown to exert multiple cellular effects antagonizing AD-associated phenotypes, including reduced amyloid-β and neuroprotection against amyloid-β-induced synaptotoxicity 127 . Although the exact cellular mechanisms underlying these actions are unclear, competition with an endogenous substrate, such as arachidonic acid, may give rise to profound downstream changes in arachidonic acid and arachidonic acid-associated signalling pathways, which have also been implicated in AD 102 . Alternatively, DHA metabolites, such as the docosanoid neuroprotectin D1, may mediate some of the protective effects by counteracting proapoptotic as well as neuroinflammatory signalling associated with AD 128 . Recent work showed that DHA can also reduce amyloid-β levels by inhibiting both β-and γ-secretase activities while potentiating α-secretase cleavage, thus offering a new perspective on how this lipid may exert neuroprotection 129 . Whereas polyunsaturated fatty acids, such as DHA, are generally viewed as neuroprotective, they are also primary substrates for lipid peroxidation, a phenomenon that is prominent in AD and other neurodegenerative disorders
. Thus, their long-term use should be considered with caution. Finally, recent genome-wide association studies have identified new risk genes in AD 130 , some of which encode proteins that are linked to lipid metabolism (for example, clusterin (also known as apolipoprotein J) and cholesteryl ester transfer protein) [131] [132] [133] . Despite the plausibility of the biological and pathological relevance of these gene products in AD, further validation studies are needed to better understand their role in AD pathogenesis.
Conclusion and perspectives
One of the outstanding questions in the field of AD and lipid research is the identification of the precise lipidbased molecular mechanisms governing AD-relevant processes that are intimately linked to the physicochemical and signalling properties of membranes. Specifically, which lipids modulate the targeting, trafficking, specificity and activity of the relevant secretases? Do specific lipid signatures predispose for, or protect against, AD? Are there common denominators in the lipid profiles of FADand SAD-affected individuals that may help to explain or provide new perspectives on the convergence of these etiologically distinct disorders towards AD pathological features? What lipid changes are causal for AD-linked pathogenicity, and what changes are simple epiphenomena? Finally, which lipids and lipid metabolizing enzymes can be targeted or exploited for therapeutics?
None of these outstanding questions could be adequately addressed without the technological advance in lipid analysis, namely, the use of 'lipidomics' 134, 135 . This systems-level analysis allows for the identification of a wide variety of lipid changes occurring as a result of experimental manipulations or a diseased state, with the anticipation that these lipid changes may instruct us on the biochemical pathways that are affected or causal in the disease. Similar to genome-wide and proteomics-based approaches, lipidomics can unmask crosstalk between biochemical pathways and provide essential mechanistic insights into the molecular basis of cellular or organismal changes. Additionally, lipidomics offers enormous potential for the identification of disease-linked bodyfluid biomarkers, which can prove particularly helpful as diagnostic tools at early stages of dementia and in the diagnosis of AD-specific mild cognitive impairment. This rapidly growing area has already begun to address lipid changes in AD brains 108, 136, 137 , in animal models of AD 102, 136, 138, 139 and in amyloid-β-treated cells 108 . The prediction is that the number of such studies will grow exponentially in the near future and touch upon multiple facets of AD and other neurodegenerative disorders. Oxidative stress is a hallmark of many degenerative disorders. The brain is particularly vulnerable to this phenomenon owing to high oxygen consumption, enrichment in polyunsaturated fatty acids (PUFAs) and high levels in redox metal ions 147 . Lipid peroxidation products (LPPs) have been found in brain, cerebrospinal fluid and plasma from patients with Alzheimer's disease (AD) 147 . Primary substrates for lipid peroxidation are PUFAs and include ω-6 fatty acids (for example, linoleic acid and arachidonic acid) as well as ω-3 fatty acids (for example, docosahexaenoic acid). Reactive oxygen species are responsible for starting the chain by the production of an unstable lipid radical that is converted to a lipid peroxyl radical, leading to the peroxidation of other fatty acids (propagation). This chain reaction stops (termination) when two radicals react to produce a non-radical species, or as a result of antioxidants (for example, vitamin C and vitamin E) and enzymes of the superoxide dismutase, catalase and peroxidase families 148 . Oxidized PUFAs are further degraded to toxic products, such as 4-hydroxy-2-nonenal (HNE), acrolein and other short-chain aldehydes. Importantly, amyloid-β has been shown to cause oxidative stress through its interaction with transition metal ions, such as Cu 2+ and Zn
2+
, which are enriched in senile plaques 149 . Amyloid-β can reduce these metal ions, thus producing hydrogen peroxide. During this process, amyloid-β becomes oxidized, thereby leading to the crosslinking of some of its residues' side-chains and the formation of aggregate-prone adducts. Alternatively, hydrogen peroxide can be generated catalytically from Cu 2+ -or Zn 2+ -bound amyloid-β using other electron donors (for example, PUFAs and cholesterol), a process leading to the generation of toxic LPPs, such as oxysterol and HNE. Finally, amyloid-β itself can be crosslinked by HNE. Key challenges in the field are to understand the role of LPP accumulation in the progression of AD-associated manifestations.
